Placebo to TQJ230 80 mg/0.8 mL Solution for injection in pre-filled syringe with needle safety device, TQJ230
CTQJ230A12203
Phase 2 small_molecule active
Quick answer
Placebo to TQJ230 80 mg/0.8 mL Solution for injection in pre-filled syringe with needle safety device, TQJ230 for Calcific Aortic Valve Stenosis is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Calcific Aortic Valve Stenosis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active